Bone marrow transplantation and thymopoietin pentapeptide treatment in two infants with immunodeficiency with predominant T-cell defects

Clin Immunol Immunopathol. 1984 Oct;33(1):123-30. doi: 10.1016/0090-1229(84)90298-8.

Abstract

Two infants with immunodeficiency with predominant T-cell defects received transplants of HLA-identical bone marrow cells along with thymopoietin pentapeptide (TP-5) treatment and no prior immunosuppressive therapy. Both patients achieved durable engraftment with early reconstitution of cell-mediated immunity. The study of cell surface antigens with monoclonal antibodies (MoAb) revealed that the early appearance of T-cell subsets defined by OKT4 and OKT8 MoAb occurred. Neither of the patients showed any signs or symptoms of graft versus host disease over a 1-year period. This experience suggests that patients with T-cell deficiency who do not benefit from thymic hormones alone can be successfully treated by bone marrow transplantation. The association of TP-5 with bone marrow transplantation seems to induce an early and stable reconstitution and to protect against fatal post-transplant infection.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal
  • Bone Marrow Transplantation*
  • Female
  • HLA Antigens / immunology
  • Humans
  • Immunologic Deficiency Syndromes / therapy*
  • Infant
  • Peptide Fragments / therapeutic use*
  • T-Lymphocytes / classification
  • T-Lymphocytes / immunology
  • Thymopentin
  • Thymopoietins / therapeutic use*
  • Thymus Hormones / therapeutic use*
  • Time Factors

Substances

  • Antibodies, Monoclonal
  • HLA Antigens
  • Peptide Fragments
  • Thymopoietins
  • Thymus Hormones
  • Thymopentin